stock

FLXN

Flexion Therapeutics Inc

$24.99

0.44% · 1Y change

Trend

Bearish

-0.44%

1Y high

$26.09

1Y low

$24.78

Trend read · Bearish

How FLXN performs — and a starting point for your own research.

Price & mood

Market Mood

PriceSMA 7/45/240 (trend)Range 1Y $24.78 – $26.09

Idea: SMA

1Y Return

+160.0%

Sharpe 3Y

0.50

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer

FLXN

Price & mood

News & Sentiment

Tempest Therapeutics appoints two directors to board

Joint Pain Injections Market Overview and Leading Players:

Flexion Therapeutics Announces Publication of Independent Data Review of ZILRETTA® (triamcinolone acetonide extended-release...

Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® (...

Flexion Therapeutics Announces Publication of Analysis of Patients with Unilateral Knee OA from Pivotal Trial of ZILRETTA® (...)

Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates

Osteoarthritis Gene Therapy Market Opportunities Supported by Viral and Non-Viral Vector Innovations

Knee Osteoarthritis (OA) Injectable Treatments Market Revenue to Attain USD 5.94 Bn by 2033

Dr. Mike Clayman, CEO of Flexion Therapeutics, on Developing New Therapies for Musculoskeletal Disorders

Pacira survey finds knee pain hurts physically, socially and mentally

Post-acquisition, Flexion Therapeutics says it will lay off 153 workers

Adamas, Flexion sell for $825M combined as biotech’s dealmaking pace picks up

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Flexion Therapeutics, Inc. with Pacira BioSciences, Inc.

Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management

Flexion Therapeutics Rallies On News Of Acquisition By Pacira BioSciences

Pacira BioSciences To Buy Flexion Therapeutics - Quick Facts

Pacira BioSciences To Buy Flexion Therapeutics - Quick Facts

Pacira BioSciences to Acquire Flexion Therapeutics Further

Flexion and Adamas Are Being Acquired. Both Stocks Are Soaring.

Pacira Aims For Non-Opioid Pipeline Growth With Flexion Buy

FLXN

Price & mood

FLXN Market Analysis

FLXN

Price & mood

News & Sentiment

Tempest Therapeutics appoints two directors to board

Joint Pain Injections Market Overview and Leading Players:

Flexion Therapeutics Announces Publication of Independent Data Review of ZILRETTA® (triamcinolone acetonide extended-release...

Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® (...

Flexion Therapeutics Announces Publication of Analysis of Patients with Unilateral Knee OA from Pivotal Trial of ZILRETTA® (...)

Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates

Osteoarthritis Gene Therapy Market Opportunities Supported by Viral and Non-Viral Vector Innovations

Knee Osteoarthritis (OA) Injectable Treatments Market Revenue to Attain USD 5.94 Bn by 2033

Dr. Mike Clayman, CEO of Flexion Therapeutics, on Developing New Therapies for Musculoskeletal Disorders

Pacira survey finds knee pain hurts physically, socially and mentally

Post-acquisition, Flexion Therapeutics says it will lay off 153 workers

Adamas, Flexion sell for $825M combined as biotech’s dealmaking pace picks up

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Flexion Therapeutics, Inc. with Pacira BioSciences, Inc.

Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management

Flexion Therapeutics Rallies On News Of Acquisition By Pacira BioSciences

Pacira BioSciences To Buy Flexion Therapeutics - Quick Facts

Pacira BioSciences To Buy Flexion Therapeutics - Quick Facts

Pacira BioSciences to Acquire Flexion Therapeutics Further

Flexion and Adamas Are Being Acquired. Both Stocks Are Soaring.

Pacira Aims For Non-Opioid Pipeline Growth With Flexion Buy

FLXN

Price & mood